文献速递中医妇科中药与中成药合理使用

甲基异茜草素激活AMPK/p53/p21通路促子宫内膜基质细胞凋亡改善宫腔粘连

Rubiadin, as a key metabolite of the Bushen Huoxue formula, promotes apoptosis of endometrial stromal cells and improves intrauterine adhesions by activating the AMPK/p53/p21 pathway.
PubMed 文献 · Front Pharmacol · 2026-04-24

本研究通过网络药理学与分子动力学模拟筛选补肾活血方关键代谢物甲基异茜草素(Rubiadin),并在体外细胞与IUA大鼠模型中验证其作用机制。结果显示Rubiadin剂量依赖性激活AMPK/p53/p21通路,促进子宫内膜基质细胞凋亡、抑制迁移侵袭与胶原合成,改善大鼠子宫内膜纤维化与炎症并提高妊娠率,而AMPK抑制剂可逆转上述效应。

要点

  • Rubiadin是补肾活血方改善宫腔粘连的关键代谢物。
  • Rubiadin通过激活AMPK/p53/p21通路促进基质细胞凋亡。
  • AMPK抑制剂Dorsomorphin可逆转Rubiadin的上述效应。

核心结论

  • Rubiadin作为补肾活血方关键代谢物,通过激活AMPK/p53/p21通路促进子宫内膜基质细胞凋亡、恢复子宫内膜功能,从而改善宫腔粘连。
  • 该研究为Rubiadin作为宫腔粘连潜在治疗药物提供了药理学依据。

研究设计与样本

  • 采用网络药理学与分子动力学模拟筛选补肾活血方代谢物。
  • 体外实验用不同浓度Rubiadin处理细胞,设或不设AMPK抑制剂Dorsomorphin,检测细胞活力、凋亡、迁移、侵袭及通路活性。
  • 体内实验用IUA大鼠模型给予Rubiadin与Dorsomorphin,评估组织病理、纤维化、炎症、妊娠结局及相关信号通路。

主要发现

  • IUA临床组织中AMPK/p53/p21通路显著受抑制。
  • 体外Rubiadin剂量依赖性激活AMPK/p53/p21通路,促进子宫内膜基质细胞凋亡,抑制细胞迁移、侵袭与胶原合成,Dorsomorphin可逆转这些效应。
  • IUA大鼠中Rubiadin激活AMPK/p53/p21通路,减少子宫内膜纤维化与炎症,显著提高妊娠率,AMPK抑制剂减弱上述治疗获益。

临床怎么用

  • 为补肾活血方治疗宫腔粘连提供关键代谢物Rubiadin及AMPK/p53/p21通路靶点的药理学依据。
  • 提示Rubiadin可能作为宫腔粘连的潜在治疗药物,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Bushen Huoxue formula (BSHX) is a classic traditional Chinese medicine prescription for treating gynecological disorders. However, its specific metabolites and mechanisms against IUA remain to be elucidated. AIM: This study aimed to identify the key metabolite of BSHX and to investigate its therapeutic effects and underlying mechanism against IUA, both in vitro and in vivo. METHODS: Network pharmacology and molecular dynamics simulation were utilized to screen the metabolites of BSHX. In vitro, cells were treated with different concentrations of Rubiadin with or without the AMPK inhibitor Dorsomorphin. Cell viability, apoptosis, migration, invasion, and pathway activity were assessed. In vivo, the IUA rat model was treated with Rubiadin and Dorsomorphin, and histopathology, fibrosis, inflammation, pregnancy outcomes, and associated signaling pathways were evaluated. RESULTS: In IUA clinical tissues, the AMPK/p53/p21 pathway was significantly inhibited. Rubiadin dose-dependently activated the AMPK/p53/p21 pathway, promoted endometrial stromal cell apoptosis, and inhibited cell migration, invasion, and collagen synthesis in vitro. These effects were reversed by Dorsomorphin. In IUA rats, Rubiadin treatment activated the AMPK/p53/p21 pathway, reduced endometrial fibrosis and inflammation, and significantly improved pregnancy rates. The AMPK inhibitor attenuated these therapeutic benefits. CONCLUSION: Rubiadin, a key metabolite of the Bushen Huoxue formula, ameliorates intrauterine adhesions by activating the AMPK/p53/p21 pathway, which promotes the apoptosis of endometrial stromal cells and restores endometrial function. This study provides a pharmacological basis for using Rubiadin as a potential therapeutic agent for IUA.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Shen C, Sha C, Yang M, et al. Rubiadin, as a key metabolite of the Bushen Huoxue formula, promotes apoptosis of endometrial stromal cells and improves intrauterine adhesions by activating the AMPK/p53/p21 pathway. Front Pharmacol. 2026. PMID: 42110558. doi:10.3389/fphar.2026.1732284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。